Literature DB >> 18297097

A role for the RISK pathway and K(ATP) channels in pre- and post-conditioning induced by levosimendan in the isolated guinea pig heart.

E F du Toit1, A Genis, L H Opie, P Pollesello, A Lochner.   

Abstract

BACKGROUND AND
PURPOSE: Myocardial reperfusion injury prevents optimal salvage of the ischaemic myocardium, and adjunct therapy that would significantly reduce reperfusion injury is still lacking. We investigated whether (1) the heart could be pre- and/or post-conditioned using levosimendan (levosimendan pre-conditioning (LPC) and levosimendan post-conditioning (LPostC)) and (2) the prosurvival kinases and/or the sarcolemmal or mitochondrial K(ATP) channels are involved. EXPERIMENTAL APPROACH: Isolated guinea pig hearts were treated with two 5 min cycles of levosimendan (0.1 microM) interspersed with vehicle perfusion, or two 5 min cycles of ischaemia/reperfusion, before coronary artery ligation (CAL) for 40 min at 36.5 degrees C. Hearts were treated with mitochondrial or sarcolemmal K(ATP) channel blockers before LPC or LPostC. For post-conditioning, hearts received three 30 s cycles of ischaemia/reperfusion or levosimendan/vehicle. Hearts were pretreated with levosimendan immediately before CAL (without washout). Cardiac function, infarct size and reperfusion injury salvage kinase activity was assessed. KEY
RESULTS: LPC and LPostC halved the infarct size compared with controls (P<0.05). Treatment with K(ATP) channel blockers before LPC or LPostC reversed this decrease. Pretreating hearts with levosimendan increased activity of extracellular signal-regulated kinase (ERK) 42/44 on reperfusion and had the most marked infarct-lowering effect (P<0.05). CONCLUSIONS AND IMPLICATIONS: (1) Hearts could be pharmacologically pre- and post-conditioned with levosimendan; (2) levosimendan pretreatment is the most effective way to reduce infarct size, possibly by increasing ERK 42/44 activity; (3) benefits of LPC and LPostC were abolished by both K(ATP) channel blockers and (4) LPC may be useful before elective cardiac surgery, whereas LPostC may be used after acute coronary artery events.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18297097      PMCID: PMC2438987          DOI: 10.1038/bjp.2008.52

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  47 in total

1.  Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.

Authors:  M S Nieminen; J Akkila; G Hasenfuss; F X Kleber; L A Lehtonen; V Mitrovic; O Nyquist; W J Remme
Journal:  J Am Coll Cardiol       Date:  2000-11-15       Impact factor: 24.094

2.  Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels.

Authors:  J R Kersten; M W Montgomery; P S Pagel; D C Warltier
Journal:  Anesth Analg       Date:  2000-01       Impact factor: 5.108

3.  Calcium preconditioning elicits strong protection against ischemic injury via protein kinase C signaling pathway.

Authors:  H Miyawaki; X Zhou; M Ashraf
Journal:  Circ Res       Date:  1996-07       Impact factor: 17.367

Review 4.  Myocardial consequences of reperfusion.

Authors:  L C Becker; G Ambrosio
Journal:  Prog Cardiovasc Dis       Date:  1987 Jul-Aug       Impact factor: 8.194

5.  Cardiac preconditioning with calcium: clinically accessible myocardial protection.

Authors:  D R Meldrum; J C Cleveland; B C Sheridan; R T Rowland; A Banerjee; A H Harken
Journal:  J Thorac Cardiovasc Surg       Date:  1996-09       Impact factor: 5.209

Review 6.  Role of calcium and other ions in reperfusion injury.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1991-03       Impact factor: 3.727

7.  Effect of levosimendan on right ventricular systolic and diastolic functions in patients with ischaemic heart failure.

Authors:  H Duygu; F Ozerkan; M Zoghi; S Nalbantgil; A Yildiz; A Akilli; M Akin; C Nazli; O Ergene
Journal:  Int J Clin Pract       Date:  2007-10-19       Impact factor: 2.503

8.  Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators.

Authors:  P G McGovern; J S Pankow; E Shahar; K M Doliszny; A R Folsom; H Blackburn; R V Luepker
Journal:  N Engl J Med       Date:  1996-04-04       Impact factor: 91.245

9.  Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate.

Authors:  J A Auchampach; G J Grover; G J Gross
Journal:  Cardiovasc Res       Date:  1992-11       Impact factor: 10.787

10.  Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs.

Authors:  G J Gross; J A Auchampach
Journal:  Circ Res       Date:  1992-02       Impact factor: 17.367

View more
  35 in total

1.  [Is everything which is feasible also sensible?: coronary artery bypass grafting in conscious patients -- a procedure with a perspective?].

Authors:  U Schirmer
Journal:  Anaesthesist       Date:  2008-12       Impact factor: 1.041

2.  Early preconditioning protection against stunning in conscious sheep. Role of KATP channels.

Authors:  Elena Catalina Lascano; Jorge A Negroni; Héctor F del Valle
Journal:  Mol Cell Biochem       Date:  2009-06-12       Impact factor: 3.396

3.  Levosimendan: from coronary care to intensive care?

Authors:  Karen Stuart-Smith
Journal:  Intensive Care Med       Date:  2011-03-05       Impact factor: 17.440

4.  The efficacy and safety of prophylactic use of levosimendan on patients undergoing coronary artery bypass graft: a systematic review and meta-analysis.

Authors:  Wanyu Wang; Xiaoshuang Zhou; Xinyang Liao; Bin Liu; Hai Yu
Journal:  J Anesth       Date:  2019-04-25       Impact factor: 2.078

5.  Thrombin and its receptor enhance ST-segment elevation in acute myocardial infarction by activating the KATP channel.

Authors:  Ming Long; Lei Yang; Genya Huang; Liping Liu; Yugang Dong; Zhimin Du; Anli Tang; Chenghen Hu; Ruimin Gu; Xiuren Gao; Lilong Tang
Journal:  Mol Med       Date:  2010-04-09       Impact factor: 6.354

6.  The role of hypoxia-inducible factor-1α and vascular endothelial growth factor in late-phase preconditioning with xenon, isoflurane and levosimendan in rat cardiomyocytes.

Authors:  Andreas Goetzenich; Nima Hatam; Stephanie Preuss; Ajay Moza; Christian Bleilevens; Anna B Roehl; Rüdiger Autschbach; Jürgen Bernhagen; Christian Stoppe
Journal:  Interact Cardiovasc Thorac Surg       Date:  2013-12-18

7.  Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.

Authors:  Marjut Louhelainen; Saara Merasto; Piet Finckenberg; Erik Vahtola; Petri Kaheinen; Jouko Levijoki; Eero Mervaala
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

8.  Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel.

Authors:  E Grossini; C Molinari; P P Caimmi; F Uberti; G Vacca
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

Review 9.  Redox signalling and cardioprotection: translatability and mechanism.

Authors:  P Pagliaro; C Penna
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

10.  Combination of Cyclosporine A and Levosimendan Induces Cardioprotection under Acute Hyperglycemia.

Authors:  Carolin Torregroza; Birce Yueksel; Raphael Ruske; Martin Stroethoff; Annika Raupach; André Heinen; Markus W Hollmann; Ragnar Huhn; Katharina Feige
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.